According to Fierce Biotech a new biotech has come into view. Precision BioSciences, a Duke spinout focused on competing in the fractious and rapidly growing field, has grabbed a $25.6 million A round with the help of some A-list investors.
http://www.fiercebiotech.com/story/amgen-fidelity-help-bankroll-another-upstart-gene-editing-player/2015-05-11
Combines CRISPR's and Talens, calls it ARCUS.
Precision is helmed by Duke graduate and CEO Kane and scientific officer Derek Jantz, who worked at Duke and once served a stint as a research associate at Sangamo, according to a short bio from Bloomberg. Jantz and his team won the $15,000 runner-up prize in Duke's 2006 startup challenge contest, boasting of the "only method to target and alter single DNA sequences in a genome."
No comments:
Post a Comment